After Alexion buyout, ex-Achillion nephrology lead jumps ship to Gemini Therapeutics

Just a few months after Alexion snapped up complement inhibitor biotech Achillion, Gemini Therapeutics has nabbed one of its key R&D execs as its new chief medical officer.

Marc Uknis, M.D., comes from his role as Achillion’s vice president and global nephrology development lead for complement factor D inhibition programs, where he had been since 2018.